Article Text

AB1011 Anti-TNF using ankylosing spondylitis patients may have less severe osteoporosis
  1. I. Dolasik,
  2. F. Cosan,
  3. B. Yilmazer,
  4. A. Cefle
  1. Rheumatology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey


Background Ankylosing spondylitis (AS) is a systemic chronic inflammatory disease characterized with enthesitis. The risk of osteoporosis is increased in AS. Low bone mineral dencity is found associated with systemic inflammation.

Objectives We aimed in this study to investigate the risk of osteoporosis in AS patients using anti- TNF treatment.

Methods The study group consisted of 49 AS patients who are using anti-TNF therapy more than 6 months, and the control group 47 AS patients without anti-TNF therapy. Two groups had similar age distribution at the time of bone mineral dansitometry. No patient had received steroid therapy previously.

Results The total femoral T score was higher in AS group with anti-TNF treatment in comparison to the control group (p=0,033; mean T scores: -0,97 and -1,53, respectively). The T scores of total lomber vertebra was higher in AS group with anti-TNF therapy than the control group (p=0,046, mean T scores: 0,0 and -0,81, respectively). The mean femoral BMD value in the anti-TNF therapy group was 0,92 g/cm2 (in comparing to 0,78 g/cm2) and was signifacantly higher (p=0,002). Moreover the lomber vertebra BMD value was significantly higher in the anti-TNF group (p=0,001, mean BMD values: 1,20 g/cm2 and 1,03 g/cm2, respectively).

Conclusions Our data revealed that AS patients receiving anti-TNF therapy have more less osteoporosis. The anti-TNF therapy may reduce the risk of osteoporosis in AS patients.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.